Table of Content
1 INTRODUCTION
1.1 OBJECTIVES OF THE STUDY
1.2 MARKET DEFINITION
1.3 OVERVIEW OF GLOBAL CANCER BIOLOGICAL THERAPY MARKET
1.4 CURRENCY AND PRICING
1.5 LIMITATION
1.6 MARKETS COVERED
2 MARKET SEGMENTATION
2.1 KEY TAKEAWAYS
2.2 ARRIVING AT THE GLOBAL CANCER BIOLOGICAL THERAPY MARKET SIZE
2.2.1 VENDOR POSITIONING GRID
2.2.2 TECHNOLOGY LIFE LINE CURVE
2.2.3 TRIPOD DATA VALIDATION MODEL
2.2.4 MARKET GUIDE
2.2.5 MULTIVARIATE MODELLING
2.2.6 TOP TO BOTTOM ANALYSIS
2.2.7 CHALLENGE MATRIX
2.2.8 APPLICATION COVERAGE GRID
2.2.9 STANDARDS OF MEASUREMENT
2.2.10 VENDOR SHARE ANALYSIS
2.2.11 DATA POINTS FROM KEY PRIMARY INTERVIEWS
2.2.12 DATA POINTS FROM KEY SECONDARY DATABASES
2.3 GLOBAL CANCER BIOLOGICAL THERAPY MARKET: RESEARCH SNAPSHOT
2.4 ASSUMPTIONS
3 MARKET OVERVIEW
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 CHALLENGES
4 EXECUTIVE SUMMARY
5 PREMIUM INSIGHTS
5.1 PESTEL ANALYSIS
5.2 PORTER’S 5 FORCES
5.3 GLOBAL CANCER BIOLOGICAL THERAPY MARKET ANALYSIS
6 EPIDEMOLOGY
6.1 EPIDEMOLOGY OF CANCER
7 INDUSTRY INSIGHTS
7.1 DEMOGRAPHIC TRENDS
7.2 KEY PRICING STRATEGIES
7.3 KEY PATIENT ENROLLMENT STRATEGIES
7.4 INTERVIEWS WITH MANUFACTURING COMPANIES
7.5 OTHER KOL SNAPSHOTS
8 REGULATORY FRAMWORK
9 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY TYPE
9.1 OVERVIEW
9.2 MONOCLONAL ANTIBODIES
9.2.1 NAKED MONOCLONAL ANTIBODIES
9.2.1.1. MARKET VALUE (USD)
9.2.1.2. MARKET VOLUME (IU)
9.2.1.3. ASP (USD)
9.2.2 CONJUGATED MONOCLONAL ANTIBODIES
9.2.2.1. RADIOLABELED ANTIBODIES
9.2.2.1.1. MARKET VALUE (USD)
9.2.2.1.2. MARKET VOLUME (IU)
9.2.2.1.3. ASP (USD)
9.2.2.2. ANTIBODY-DRUG CONJUGATES (CHEMOLABELED ANTIBODIES):
9.2.2.2.1. MARKET VALUE (USD)
9.2.2.2.2. MARKET VOLUME (IU)
9.2.2.2.3. ASP (USD)
9.2.3 BISPECIFIC MONOCLONAL ANTIBODIES
9.2.3.1. MARKET VALUE (USD)
9.2.3.2. MARKET VOLUME (IU)
9.2.3.3. ASP (USD)
9.3 CYTOKINES
9.4 VACCINES
9.4.1 PROPHYLACTIC VACCINES
9.4.1.1. MARKET VALUE (USD)
9.4.1.2. MARKET VOLUME (IU)
9.4.1.3. ASP (USD)
9.4.2 THERAPEUTIC VACCINES
9.4.2.1. MARKET VALUE (USD)
9.4.2.2. MARKET VOLUME (IU)
9.4.2.3. ASP (USD)
9.5 CHECKPOINT INHIBITORS
9.5.1 CYTOTOXIC T-LYMPHOCYTE-ASSOCIATED PROTEIN-4 (CTLA-4)
9.5.1.1. MARKET VALUE (USD)
9.5.1.2. MARKET VOLUME (IU)
9.5.1.3. ASP (USD)
9.5.2 PROGRAMMED DEATH 1 (PD-1) & PROGRAMMED DEATH LIGAND 1 (PD-L1)
9.5.2.1. MARKET VALUE (USD)
9.5.2.2. MARKET VOLUME (IU)
9.5.2.3. ASP (USD)
9.5.3 TF INHIBITOR
9.5.3.1. MARKET VALUE (USD)
9.5.3.2. MARKET VOLUME (IU)
9.5.3.3. ASP (USD)
9.6 CELL THERAPIES
9.6.1 CHIMERIC ANTIGEN RECEPTOR (CAR) T CELL THERAPY
9.6.2 DENDRITIC CELLS
9.6.3 TIL THERAPY
9.6.4 TCR THERAPY
9.6.5 NK CELL THERAPY
9.7 IMMUNOMODULATORS
9.7.1 GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR
9.7.1.1. MARKET VALUE (USD)
9.7.1.2. MARKET VOLUME (IU)
9.7.1.3. ASP (USD)
9.7.2 INTERFERONS
9.7.2.1. MARKET VALUE (USD)
9.7.2.2. MARKET VOLUME (IU)
9.7.2.3. ASP (USD)
9.7.3 INTERLEUKINS
9.7.3.1. MARKET VALUE (USD)
9.7.3.2. MARKET VOLUME (IU)
9.7.3.3. ASP (USD)
9.8 ONCOLYTIC VIRUS
9.8.1.1. MARKET VALUE (USD)
9.8.1.2. MARKET VOLUME (IU)
9.8.1.3. ASP (USD)
10 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY APPLICATION
10.1 OVERVIEW
10.2 LUNG CANCER
10.2.1 MONOCLONAL ANTIBODIES
10.2.2 VACCINES
10.2.3 CHECKPOINT INHIBITORS
10.2.4 CELL THERAPIES
10.2.5 IMMUNOMODULATORS
10.2.6 ONCOLYTIC VIRUS
10.2.7 CYTOKINES
10.3 BREAST CANCER
10.3.1 MONOCLONAL ANTIBODIES
10.3.2 VACCINES
10.3.3 CHECKPOINT INHIBITORS
10.3.4 CELL THERAPIES
10.3.5 IMMUNOMODULATORS
10.3.6 ONCOLYTIC VIRUS
10.3.7 CYTOKINES
10.4 MULTIPLE MYELOMA
10.4.1 MONOCLONAL ANTIBODIES
10.4.2 VACCINES
10.4.3 CHECKPOINT INHIBITORS
10.4.4 CELL THERAPIES
10.4.5 IMMUNOMODULATORS
10.4.6 ONCOLYTIC VIRUS
10.4.7 CYTOKINES
10.5 COLORECTAL CANCER
10.5.1 MONOCLONAL ANTIBODIES
10.5.2 VACCINES
10.5.3 CHECKPOINT INHIBITORS
10.5.4 CELL THERAPIES
10.5.5 IMMUNOMODULATORS
10.5.6 ONCOLYTIC VIRUS
10.5.7 CYTOKINES
10.6 HEAD & NECK CANCER
10.6.1 MONOCLONAL ANTIBODIES
10.6.2 VACCINES
10.6.3 CHECKPOINT INHIBITORS
10.6.4 CELL THERAPIES
10.6.5 IMMUNOMODULATORS
10.6.6 ONCOLYTIC VIRUS
10.6.7 CYTOKINES
10.7 PROSTATE CANCER
10.7.1 MONOCLONAL ANTIBODIES
10.7.2 VACCINES
10.7.3 CHECKPOINT INHIBITORS
10.7.4 CELL THERAPIES
10.7.5 IMMUNOMODULATORS
10.7.6 ONCOLYTIC VIRUS
10.7.7 CYTOKINES
10.8 MELANOMA
10.8.1 MONOCLONAL ANTIBODIES
10.8.2 VACCINES
10.8.3 CHECKPOINT INHIBITORS
10.8.4 CELL THERAPIES
10.8.5 IMMUNOMODULATORS
10.8.6 ONCOLYTIC VIRUS
10.8.7 CYTOKINES
10.9 OVARIAN CANCER
10.9.1 MONOCLONAL ANTIBODIES
10.9.2 VACCINES
10.9.3 CHECKPOINT INHIBITORS
10.9.4 CELL THERAPIES
10.9.5 IMMUNOMODULATORS
10.9.6 ONCOLYTIC VIRUS
10.9.7 CYTOKINES
10.1 CERVICAL CANCER
10.10.1 MONOCLONAL ANTIBODIES
10.10.2 VACCINES
10.10.3 CHECKPOINT INHIBITORS
10.10.4 CELL THERAPIES
10.10.5 IMMUNOMODULATORS
10.10.6 ONCOLYTIC VIRUS
10.10.7 CYTOKINES
10.11 STOMACH CANCER
10.11.1 MONOCLONAL ANTIBODIES
10.11.2 VACCINES
10.11.3 CHECKPOINT INHIBITORS
10.11.4 CELL THERAPIES
10.11.5 IMMUNOMODULATORS
10.11.6 ONCOLYTIC VIRUS
10.11.7 CYTOKINES
10.12 OTHERS
11 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY GENDER
11.1 OVERVIEW
11.2 MALE
11.2.1 AGE LESS THAN 20 YRS
11.2.2 21-40 YRS
11.2.3 ABOVE 40 YRS
11.3 FEMALE
11.3.1 AGE LESS THAN 20 YRS
11.3.2 21-40 YRS
11.3.3 ABOVE 40 YRS
12 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY FORM
12.1 OVERVIEW
12.2 ORAL
12.3 INTRAVENOUS (IV)
12.4 TOPICAL
12.5 INTRAVESICAL
13 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY DRUG TYPE
13.1 OVERVIEW
13.2 BRANDED
13.2.1 ZEVALIN
13.2.2 ADCETRIS
13.2.3 KYMRIAH
13.2.4 YESCARTA
13.2.5 BREYANZI
13.2.6 KEYTRUDA
13.2.7 TECENTRIQ
13.2.8 OPDIVO
13.2.9 PROVENGE
13.2.10 BAVENCIO
13.3 BIOSIMILAR
14 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY END USER
14.1 OVERVIEW
14.2 HOSPITALS
14.3 SPECIALITY CLINICS
14.4 CLINICS
14.5 ACADEMIC AND RESEARCH INSTITUTES
14.6 HOMECARE
14.7 OTHERS
15 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY DISTRIBUTION CHANNEL
15.1 OVERVIEW
15.2 DIRECT TENDER
15.3 RETAIL SALES
15.3.1 HOSPITAL PHARMACY
15.3.2 RETAIL PHARMACY
15.3.3 ONLINE PHARMACY
16 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, BY REGION
GLOBAL CANCER BIOLOGICAL THERAPY MARKET, (ALL SEGMENTATION PROVIDED ABOVE IS REPRESENTED IN THIS CHAPTER BY COUNTRY)
16.1 NORTH AMERICA
16.1.1 U.S.
16.1.2 CANADA
16.1.3 MEXICO
16.2 EUROPE
16.2.1 GERMANY
16.2.2 U.K.
16.2.3 ITALY
16.2.4 FRANCE
16.2.5 SPAIN
16.2.6 RUSSIA
16.2.7 SWITZERLAND
16.2.8 TURKEY
16.2.9 BELGIUM
16.2.10 NETHERLANDS
16.2.11 DENMARK
16.2.12 SWEDEN
16.2.13 POLAND
16.2.14 NORWAY
16.2.15 FINLAND
16.2.16 REST OF EUROPE
16.3 ASIA-PACIFIC
16.3.1 JAPAN
16.3.2 CHINA
16.3.3 SOUTH KOREA
16.3.4 INDIA
16.3.5 SINGAPORE
16.3.6 THAILAND
16.3.7 INDONESIA
16.3.8 MALAYSIA
16.3.9 PHILIPPINES
16.3.10 AUSTRALIA
16.3.11 NEW ZEALAND
16.3.12 VIETNAM
16.3.13 TAIWAN
16.3.14 REST OF ASIA-PACIFIC
16.4 SOUTH AMERICA
16.4.1 BRAZIL
16.4.2 ARGENTINA
16.4.3 REST OF SOUTH AMERICA
16.5 MIDDLE EAST AND AFRICA
16.5.1 SOUTH AFRICA
16.5.2 EGYPT
16.5.3 BAHRAIN
16.5.4 UNITED ARAB EMIRATES
16.5.5 KUWAIT
16.5.6 OMAN
16.5.7 QATAR
16.5.8 SAUDI ARABIA
16.5.9 REST OF MIDDLE EAST AND AFRICA
16.6 KEY PRIMARY INSIGHTS: BY MAJOR COUNTRIES
17 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, COMPANY LANDSCAPE
17.1 COMPANY SHARE ANALYSIS: GLOBAL
17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA
17.3 COMPANY SHARE ANALYSIS: EUROPE
17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC
17.5 MERGERS & ACQUISITIONS
17.6 NEW PRODUCT DEVELOPMENT & APPROVALS
17.7 EXPANSIONS
17.8 REGULATORY CHANGES
17.9 PARTNERSHIP AND OTHER STRATEGIC DEVELOPMENTS
18 GLOBAL CANCER BIOLOGICAL THERAPY MARKET, COMPANY PROFILE
18.1 AMGEN
18.1.1 COMPANY OVERVIEW
18.1.2 REVENUE ANALYSIS
18.1.3 GEOGRAPHIC PRESENCE
18.1.4 PRODUCT PORTFOLIO
18.1.5 RECENT DEVELOPMENTS
18.2 SPECTRUM PHARMACEUTICALS
18.2.1 COMPANY OVERVIEW
18.2.2 REVENUE ANALYSIS
18.2.3 GEOGRAPHIC PRESENCE
18.2.4 PRODUCT PORTFOLIO
18.2.5 RECENT DEVELOPMENTS
18.3 F. HOFFMANN-LA ROCHE AG
18.3.1 COMPANY OVERVIEW
18.3.2 REVENUE ANALYSIS
18.3.3 GEOGRAPHIC PRESENCE
18.3.4 PRODUCT PORTFOLIO
18.3.5 RECENT DEVELOPMENTS
18.4 BAYER AG
18.4.1 COMPANY OVERVIEW
18.4.2 REVENUE ANALYSIS
18.4.3 GEOGRAPHIC PRESENCE
18.4.4 PRODUCT PORTFOLIO
18.4.5 RECENT DEVELOPMENTS
18.5 BRISTOL-MYERS SQUIBB
18.5.1 COMPANY OVERVIEW
18.5.2 REVENUE ANALYSIS
18.5.3 GEOGRAPHIC PRESENCE
18.5.4 PRODUCT PORTFOLIO
18.5.5 RECENT DEVELOPMENTS
18.6 ELI LILLY AND COMPANY
18.6.1 COMPANY OVERVIEW
18.6.2 REVENUE ANALYSIS
18.6.3 GEOGRAPHIC PRESENCE
18.6.4 PRODUCT PORTFOLIO
18.6.5 RECENT DEVELOPMENTS
18.7 JANSSEN BIOTECH, INC
18.7.1 COMPANY OVERVIEW
18.7.2 REVENUE ANALYSIS
18.7.3 GEOGRAPHIC PRESENCE
18.7.4 PRODUCT PORTFOLIO
18.7.5 RECENT DEVELOPMENTS
18.8 MERCK & CO., INC.
18.8.1 COMPANY OVERVIEW
18.8.2 REVENUE ANALYSIS
18.8.3 GEOGRAPHIC PRESENCE
18.8.4 PRODUCT PORTFOLIO
18.8.5 RECENT DEVELOPMENTS
18.9 NOVARTIS
18.9.1 COMPANY OVERVIEW
18.9.2 REVENUE ANALYSIS
18.9.3 GEOGRAPHIC PRESENCE
18.9.4 PRODUCT PORTFOLIO
18.9.5 RECENT DEVELOPMENTS
18.1 PFIZER
18.10.1 COMPANY OVERVIEW
18.10.2 REVENUE ANALYSIS
18.10.3 GEOGRAPHIC PRESENCE
18.10.4 PRODUCT PORTFOLIO
18.10.5 RECENT DEVELOPMENTS
18.11 GENENTECH, INC.
18.11.1 COMPANY OVERVIEW
18.11.2 REVENUE ANALYSIS
18.11.3 GEOGRAPHIC PRESENCE
18.11.4 PRODUCT PORTFOLIO
18.11.5 RECENT DEVELOPMENTS
18.12 JUNO THERAPEUTICS
18.12.1 COMPANY OVERVIEW
18.12.2 REVENUE ANALYSIS
18.12.3 GEOGRAPHIC PRESENCE
18.12.4 PRODUCT PORTFOLIO
18.12.5 RECENT DEVELOPMENTS
18.13 REGENERON PHARMACEUTICALS, INC.
18.13.1 COMPANY OVERVIEW
18.13.2 REVENUE ANALYSIS
18.13.3 GEOGRAPHIC PRESENCE
18.13.4 PRODUCT PORTFOLIO
18.13.5 RECENT DEVELOPMENTS
18.14 CELLDEX THERAPEUTICS
18.14.1 COMPANY OVERVIEW
18.14.2 REVENUE ANALYSIS
18.14.3 GEOGRAPHIC PRESENCE
18.14.4 PRODUCT PORTFOLIO
18.14.5 RECENT DEVELOPMENTS
18.15 KITE PHARMA
18.15.1 COMPANY OVERVIEW
18.15.2 REVENUE ANALYSIS
18.15.3 GEOGRAPHIC PRESENCE
18.15.4 PRODUCT PORTFOLIO
18.15.5 RECENT DEVELOPMENTS
18.16 ATARA BIOTHERAPEUTICS
18.16.1 COMPANY OVERVIEW
18.16.2 REVENUE ANALYSIS
18.16.3 GEOGRAPHIC PRESENCE
18.16.4 PRODUCT PORTFOLIO
18.16.5 RECENT DEVELOPMENTS
18.17 CELLECTIS
18.17.1 COMPANY OVERVIEW
18.17.2 REVENUE ANALYSIS
18.17.3 GEOGRAPHIC PRESENCE
18.17.4 PRODUCT PORTFOLIO
18.17.5 RECENT DEVELOPMENTS
18.18 ASTRAZENECA
18.18.1 COMPANY OVERVIEW
18.18.2 REVENUE ANALYSIS
18.18.3 GEOGRAPHIC PRESENCE
18.18.4 PRODUCT PORTFOLIO
18.18.5 RECENT DEVELOPMENTS
18.19 ABBVIE INC.
18.19.1 COMPANY OVERVIEW
18.19.2 REVENUE ANALYSIS
18.19.3 GEOGRAPHIC PRESENCE
18.19.4 PRODUCT PORTFOLIO
18.19.5 RECENT DEVELOPMENTS
18.2 TAKEDA
18.20.1 COMPANY OVERVIEW
18.20.2 REVENUE ANALYSIS
18.20.3 GEOGRAPHIC PRESENCE
18.20.4 PRODUCT PORTFOLIO
18.20.5 RECENT DEVELOPMENTS
18.21 GLAXOSMITHKLINE PLC.
18.21.1 COMPANY OVERVIEW
18.21.2 REVENUE ANALYSIS
18.21.3 GEOGRAPHIC PRESENCE
18.21.4 PRODUCT PORTFOLIO
18.21.5 RECENT DEVELOPMENTS
18.22 MYLAN N.V.
18.22.1 COMPANY OVERVIEW
18.22.2 REVENUE ANALYSIS
18.22.3 GEOGRAPHIC PRESENCE
18.22.4 PRODUCT PORTFOLIO
18.22.5 RECENT DEVELOPMENTS
18.23 TEVA PHARMACEUTICAL INDUSTRIES LTD.
18.23.1 COMPANY OVERVIEW
18.23.2 REVENUE ANALYSIS
18.23.3 GEOGRAPHIC PRESENCE
18.23.4 PRODUCT PORTFOLIO
18.23.5 RECENT DEVELOPMENTS
18.24 ONO PHARMACEUTICAL CO., LTD.
18.24.1 COMPANY OVERVIEW
18.24.2 REVENUE ANALYSIS
18.24.3 GEOGRAPHIC PRESENCE
18.24.4 PRODUCT PORTFOLIO
18.24.5 RECENT DEVELOPMENTS
18.25 SANOFI
18.25.1 COMPANY OVERVIEW
18.25.2 REVENUE ANALYSIS
18.25.3 GEOGRAPHIC PRESENCE
18.25.4 PRODUCT PORTFOLIO
18.25.5 RECENT DEVELOPMENTS
18.26 SUN PHARMACEUTICAL INDUSTRIES LTD.
18.26.1 COMPANY OVERVIEW
18.26.2 REVENUE ANALYSIS
18.26.3 GEOGRAPHIC PRESENCE
18.26.4 PRODUCT PORTFOLIO
18.26.5 RECENT DEVELOPMENTS
18.27 AUROBINDO PHARMA
18.27.1 COMPANY OVERVIEW
18.27.2 REVENUE ANALYSIS
18.27.3 GEOGRAPHIC PRESENCE
18.27.4 PRODUCT PORTFOLIO
18.27.5 RECENT DEVELOPMENTS
18.28 INCYTE
18.28.1 COMPANY OVERVIEW
18.28.2 REVENUE ANALYSIS
18.28.3 GEOGRAPHIC PRESENCE
18.28.4 PRODUCT PORTFOLIO
18.28.5 RECENT DEVELOPMENTS
18.29 IMMUNITYBIO INC.
18.29.1 COMPANY OVERVIEW
18.29.2 REVENUE ANALYSIS
18.29.3 GEOGRAPHIC PRESENCE
18.29.4 PRODUCT PORTFOLIO
18.29.5 RECENT DEVELOPMENTS
18.3 GALECTIN THERAPEUTICS
18.30.1 COMPANY OVERVIEW
18.30.2 REVENUE ANALYSIS
18.30.3 GEOGRAPHIC PRESENCE
18.30.4 PRODUCT PORTFOLIO
18.30.5 RECENT DEVELOPMENTS
18.31 COMPUGEN
18.31.1 COMPANY OVERVIEW
18.31.2 REVENUE ANALYSIS
18.31.3 GEOGRAPHIC PRESENCE
18.31.4 PRODUCT PORTFOLIO
18.31.5 RECENT DEVELOPMENTS
NOTE: THE COMPANIES PROFILED IS NOT EXHAUSTIVE LIST AND IS AS PER OUR PREVIOUS CLIENT REQUIREMENT. WE PROFILE MORE THAN 100 COMPANIES IN OUR STUDY AND HENCE THE LIST OF COMPANIES CAN BE MODIFIED OR REPLACED ON REQUEST
19 CONCLUSION
20 QUESTIONNAIRE
21 ABOUT DATA BRIDGE MARKET RESEARCH
